Intrexon Q2 Loss Narrows - Quick Facts

(RTTNews) - Intrexon Corp. (XON), a leader in synthetic biology, reported a second quarter net loss to company of $40.7 million or $0.37 per share compared to a loss of $52.0 million or $0.53 per share, a year ago. Excluding the special stock dividend of ZIOPHARM Oncology, Inc. shares, pro forma net income attributable to Intrexon would have been of $0.9 million, or $0.01 per share.

On average, five analysts polled by Thomson Reuters expected the company to report a loss per share of $0.04 for the quarter. Analysts' estimates typically exclude special items.

Total revenues were $44.9 million compared to $11.8 million, an increase of 281%. Analysts expected revenue of $55.52 million for the quarter.